Jiang, Jana and Boehringer, Daniel and Auw-Haedrich, Claudia and Maier, Philip Christian and Barth, Teresa and Eter, Nicole and Fuest, Matthias and Geerling, Gerd and Heindl, Ludwig M. and Herwig-Carl, Martina and Hintschich, Christoph and Hufendiek, Katerina and Kampik, Daniel and Lieb, Wolfgang and Meller, Daniel and Mueller, Arthur and Pfeiffer, Norbert and Rehak, Matus and Schargus, Marc and Seitz, Berthold and Spitzer, Martin and Stahl, Andreas and Suesskind, Daniela and van Oterendorp, Christian and Wagner, Felix Mathias and Westekemper, Henrike and Ziemssen, Focke and Reinhard, Thomas (2023) Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon- <i>α</i> 2b: A Survey of Tertiary Eye Centres in Germany. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 240 (07). pp. 891-896. ISSN 0023-2165, 1439-3999
Full text not available from this repository. (Request a copy)Abstract
Purpose To evaluate the standard of care, in particular the use of topical or subconjunctival interferon- a 2b, in treating ocular surface squamous neoplasia or melanocytic tumours in tertiary eye centres in Germany.Methods A survey containing 14 questions was sent to 43 tertiary eye centres in Germany. The questions addressed the surgical and medical management of ocular surface squamous neoplasia and melanocytic tumours (primary acquired melanosis and malignant melanoma), as well as the clinical experiences and difficulties in prescribing off-label interferon- a 2b eye drops and subconjunctival injections.Results Twenty-four tertiary eye centres responded to the survey. Eighty-three percent of centres had used interferon- a 2b in their clinical practice and 25% prescribed it as the first-line cytostatic agent following surgical excision of ocular surface squamous neoplasia, while 10% would do so for melanocytic tumours. Correspondingly, the majority of respondents selected mitomycin C as their first-line agent. Side effects were uncommon with topical interferon- a 2b eye drops but were more frequently reported after subconjunctival interferon- a 2b injections. In total, eight centres had experience with interferon- a 2b injections. The most significant obstacles perceived by ophthalmologists when prescribing interferon- a 2b were its high cost and the reimbursement thereof.Conclusion Off-label mitomycin C was the preferred adjuvant therapy for epithelial and melanocytic tumours, with interferon- a 2b being the standard second-line option. Interferon- a 2b has predominantly been used to treat ocular surface squamous neoplasia and, to a lesser extent, melanocytic tumours at German tertiary eye centres. Following its market withdrawal, supply shortages of interferon- a 2b are likely to have a profound impact on patient care and their quality of life.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SURFACE SQUAMOUS NEOPLASIA; AMERICAN-JOINT-COMMITTEE; OCULAR SURFACE; TOPICAL INTERFERON-ALPHA-2B; PHARMACOTHERAPY; CHEMOTHERAPY; 5-fluorouracil; mitomycin C; interferon- alpha 2b; ocular surface squamous neoplasia; conjunctival melanoma |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Augenheilkunde |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Mar 2024 09:12 |
| Last Modified: | 19 Mar 2024 09:12 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60850 |
Actions (login required)
 |
View Item |
